- Home
- ZIMV vs ERAS Comparison
ZIMV vs ERAS Comparison
Compare ZIMV & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- ERAS
- Stock Information
- Founded
- ZIMV 2021
- ERAS 2018
- Country
- ZIMV United States
- ERAS United States
- Employees
- ZIMV N/A
- ERAS N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- ERAS Health Care
- Exchange
- ZIMV Nasdaq
- ERAS Nasdaq
- Market Cap
- ZIMV 530.7M
- ERAS 484.4M
- IPO Year
- ZIMV N/A
- ERAS 2021
- Fundamental
- Price
- ZIMV $18.85
- ERAS $1.64
- Analyst Decision
- ZIMV Hold
- ERAS Strong Buy
- Analyst Count
- ZIMV 3
- ERAS 6
- Target Price
- ZIMV $14.50
- ERAS $4.83
- AVG Volume (30 Days)
- ZIMV 1.3M
- ERAS 796.3K
- Earning Date
- ZIMV 07-30-2025
- ERAS 08-12-2025
- Dividend Yield
- ZIMV N/A
- ERAS N/A
- EPS Growth
- ZIMV N/A
- ERAS N/A
- EPS
- ZIMV N/A
- ERAS N/A
- Revenue
- ZIMV $443,402,000.00
- ERAS N/A
- Revenue This Year
- ZIMV $2.09
- ERAS N/A
- Revenue Next Year
- ZIMV $1.64
- ERAS N/A
- P/E Ratio
- ZIMV N/A
- ERAS N/A
- Revenue Growth
- ZIMV N/A
- ERAS N/A
- 52 Week Low
- ZIMV $8.15
- ERAS $1.01
- 52 Week High
- ZIMV $18.98
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ZIMV 84.37
- ERAS 58.30
- Support Level
- ZIMV $18.82
- ERAS $1.38
- Resistance Level
- ZIMV $18.95
- ERAS $1.71
- Average True Range (ATR)
- ZIMV 0.11
- ERAS 0.11
- MACD
- ZIMV -0.30
- ERAS 0.01
- Stochastic Oscillator
- ZIMV 66.67
- ERAS 78.95
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.